Irinotecan plus carboplatin for patients with carcinoma of unknown primary site-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site

Published:2008-12-16 Issue:1 Volume:100 Page:50-55
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Yonemori K,Ando M,Yunokawa M,Hirata T,Kouno T,Shimizu C,Tamura K,Katsumata N,Hirakawa A,Matsumoto K,Yamanaka Y,Arioka H,Fujiwara Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6604829.pdf

Reference42 articles.

1. Balaña C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, Mate JL, Rosell R (2003) A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 4: 1425–1429

2. Briasoulis E, Fountzilas G, Bamias A, Dimopoulis MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N (2008a) Multicenter phase II trial of irinotecan plus oxaliplatin in patients with poor-prognosis cancer of unknown primary: a Hellenic cooperative oncology group study. Cancer Chemother Pharmacol 62: 277–284

3. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma; a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18: 3101–3107

4. Briasoulis E, Pavlidis N, Felip E (2008b) Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 19 (Suppl 2): ii106–ii107

5. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary;Frontiers in Oncology;2023-07-10

2. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site;Clinical Oncology;2018-10

3. Clinical outcomes in patients with cancer of unknown primary site treated by gastrointestinal oncologists;Journal of Translational Internal Medicine;2017-03-01

4. CUP – Internistische Therapie bei ungünstigem Risikoprofil;Der Onkologe;2012-12-19

5. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis;British Journal of Cancer;2012-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3